Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
Saturday, September 12, 2026 · first reported by Fierce Biotech
Frazier Life Sciences closed a $1.1B venture fund focused on early and growth-stage investments in small and midsize biotechnology companies.
- Size
- $1.1B
- Stage
- Final close
- Asset class
- Venture
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- DIG Ventures raises $120m third fund to target Europe’s AI infrastructure startupsAltAssets +1
- Sofia-based LAUNCHub Ventures secures €65 million first close of Fund III; targets €75 million+EU-Startups +4
- Stride Consumer grows fund 30% with $550m hard-cap close after four-month raiseAltAssets +1
- Forty.5 Ventures Closes a $30M First Fund to Move SEE Founders Onto the World StageThe Recursive
- SEC charges Meyer Global Management, CEO with defrauding investors in SpaceX pre-IPO fundPensions & Investments +1
- Two Google alumni raise $11.3M to back AI startups that enterprises will actually pay forTechCrunch +1